Pharmaceutical Business Review
Anonymous User | Login

GSK, Valeant Provide Updates On NDA For Retigabine

Published: 02-Nov-2009

To treat adult epilepsy patients with partial-onset seizures

GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (Valeant) have provided updates on the New Drug Application for retigabine.

GSK and Valeant had filed a New Drug Application with the FDA and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA) on 30 October, for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures.

Both the companies had entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures. Retigabine has shown robust efficacy and safety as demonstrated in two large, completed Phase III trials conducted in patients with refractory epilepsy receiving treatment with up to three antiepileptic drugs (AEDs).

The companies have reported that retigabine is not approved or licensed anywhere in the world.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Parenteral Drug Association (PDA)

Pharmaceutical Information and Education Services ...

BlueSens

Gas Analyser for Bioprocesses ...

EqualEstro

Vigilance and care ...

ADAPT Localization

The Translation and Localization Specialists ...

Tarius

Your One Source for Global Regulatory Information ...

BIOQUELL

Specialist Providers of Bio-decontamination Equipment and Services ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Your IP at Risk in Collaborations!

Free white paper: Ten steps to protect your R&D investment within partnerships. ...

Why, When and How to Conduct 14C Human Studies

Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...

Why CAPA Still Matters

This free white paper explores the needs and effectiveness of correct CAPA control, how to ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly

Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Related Companies

Pfizer Inc.

Pfizer Inc. (Pfizer) is a global research based pharmaceutical company principally focu ...

Human Genome Sciences, Inc.

Human Genome Sciences, Inc. (HGS) is engaged in the discovery, development and marketin ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Suppliers Product News

No items to display

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address